Norman Michael Greenberg
Plus aucun poste en cours
Profil
Norman Michael Greenberg is currently a Director at Mongoose Bio, Inc. He was previously the Chief Scientific Officer at Atreca, Inc. from 2016 to 2021, Vice President-Global Research at Medimmune, Inc. from 2011 to 2014, Senior Vice President-Translational Medicine at Checkmate Pharmaceuticals, Inc. from 2015 to 2016, and President & Chief Executive Officer at NMG Scientific Consulting USA from 2014 to 2016.
He also held positions as a Senior Director-Research at Pfizer Inc. from 2009 to 2011 and an Associate Professor at Baylor College of Medicine from 1998 to 2003.
Dr. Greenberg is a doctorate graduate from the University of British Columbia and an undergraduate graduate from the University of Toronto.
Postes actifs de Norman Michael Greenberg
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Norman Michael Greenberg
| Sociétés | Poste | Fin |
|---|---|---|
| ATRECA, INC. | Directeur Technique/Scientifique/R&D | 31/03/2021 |
| CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2016 |
| NMG Scientific Consulting USA | Directeur Général | 01/05/2016 |
| Medimmune, Inc. | Directeur Technique/Scientifique/R&D | 01/05/2014 |
| PFIZER, INC. | Directeur Technique/Scientifique/R&D | 01/07/2011 |
Formation de Norman Michael Greenberg
| University of Toronto | Undergraduate Degree |
| University of British Columbia | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Atreca, Inc.
 Atreca, Inc. BiotechnologyHealth Technology Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
| Medimmune, Inc. | Health Technology |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Commercial Services |
| NMG Scientific Consulting USA |
